Rapid health technology assessment of serplulimab in the first-line treatment of small-cell lung cancer

HOU Yibing; KANG Shuo; GONG Yuan; WANG Xiaohui; NIE Ying; LIU Huanlong

doi:10.6039/j.issn.1001-0408.2025.11.21

您当前的位置：

首页 >

文章列表页 >

Rapid health technology assessment of serplulimab in the first-line treatment of small-cell lung cancer

更新时间：2026-02-06

- Rapid health technology assessment of serplulimab in the first-line treatment of small-cell lung cancer
- ZHONGGUO YAOFANG Vol. 36, Issue 11, Pages: 1405-1410(2025)
- 作者机构：
  
  1.河北医科大学第二医院药学部，石家庄　050000
  2.河北医科大学第二医院医保办，石家庄　050000
  3.河北医科大学药学院，石家庄　050017
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.11.21
  CLC： R969.3;R956
- Received：18 October 2024，
  
  Revised：2025-05-08，
  
  Accepted：09 May 2025，
  
  Published：15 June 2025
- 稿件说明：
移动端阅览
侯奕冰,康朔,公元,等.斯鲁利单抗一线治疗小细胞肺癌的快速卫生技术评估 [J].中国药房,2025,36(11):1405-1410.

HOU Yibing,KANG Shuo,GONG Yuan,et al.Rapid health technology assessment of serplulimab in the first-line treatment of small-cell lung cancer[J].ZHONGGUO YAOFANG,2025,36(11):1405-1410.
侯奕冰,康朔,公元,等.斯鲁利单抗一线治疗小细胞肺癌的快速卫生技术评估 [J].中国药房,2025,36(11):1405-1410. DOI： 10.6039/j.issn.1001-0408.2025.11.21.

HOU Yibing,KANG Shuo,GONG Yuan,et al.Rapid health technology assessment of serplulimab in the first-line treatment of small-cell lung cancer[J].ZHONGGUO YAOFANG,2025,36(11):1405-1410. DOI： 10.6039/j.issn.1001-0408.2025.11.21.

摘要

目的

评价斯鲁利单抗一线治疗小细胞肺癌（SCLC）的有效性、安全性和经济性，为医疗机构药物遴选提供循证依据。

方法

采用快速卫生技术评估方法，系统检索PubMed、Cochrane Library、Embase、中国知网、万方数据、维普网以及国内外卫生技术评估机构官方网站，检索时限为建库开始至2024年10月，由2名评价者根据纳入和排除标准独立筛选文献并评估文献质量后，进行定性分析。

结果

共纳入13篇系统评价/Meta分析和9篇经济学研究，文献质量总体良好。有效性方面，与单纯化疗相比，斯鲁利单抗联合化疗可显著改善SCLC患者的无进展生存期、总生存期和客观缓解率。安全性方面，斯鲁利单抗联合化疗方案治疗SCLC导致的3级及以上不良事件发生率与单纯化疗相比无明显差异，显示出良好的安全性；与其他免疫抑制剂的联合疗法相比，其不良事件的发生率也较低。经济性方面，相比于单纯化疗方案，斯鲁利单抗联合化疗方案不具有经济性，可能与斯鲁利单抗价格过高有关。

结论

斯鲁利单抗一线治疗SCLC的有效性、安全性较好，但经济性无明显优势。

Abstract

OBJECTIVE

To evaluate the efficacy， safety and cost-effectiveness of serplulimab as a first-line treatment of small-cell lung cancer （SCLC）， and provide an evidence-based basis for drug selection in hospitals.

METHODS

Rapid health technology assessment was adopted； PubMed， Cochrane Library， Embase， CNKI， Wanfang， VIP and official websites of domestic and international health technology assessment agencies were systematically searched from the inception to Oct. 2024. Two reviewers independently screened the literature， assessed the quality of included studies and carried out the qualitative analysis according to the inclusion and exclusion criteria.

RESULTS

A total of 13 systematic reviews/meta-analyses and 9 economic studies were included， and the literature quality was generally good. In terms of effectiveness， compared with chemotherapy alone， serplulimab combined with chemotherapy significantly improved progression-free survival， overall survival， and objective response rate in patients with SCLC. In terms of safety， serplulimab combined with chemotherapy showed no significant difference in the incidence of ≥3 grade adverse events compared with chemotherapy alone in the treatment of SCLC， indicating a good safety profile； compared with combination therapies involving other immunosuppressive agents， the incidence rate of adverse events was also lower. In terms of cost-effectiveness， compared with chemotherapy alone， serplulimab combined with chemotherapy is not cost-effective， which may be related to the high price of serplulimab.

CONCLUSIONS

Serplulimab is effective and safe in the treatment of SCLC， but has no obvious advantage in terms of cost-effectiveness.

关键词

Keywords

references

SUNG H ， FERLAY J ， SIEGEL R L ， et al . Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 .

SIEGEL R L ， MILLER K D ， JEMAL A . Cancer statistics，2020 [J ] . CA Cancer J Clin ， 2020 ， 70 （ 1 ）： 7 - 30 .

WANG S C ， TANG J J ， SUN T T ， et al . Survival changes in patients with small cell lung cancer and disparities between different sexes，socioeconomic statuses and ages [J ] . Sci Rep ， 2017 ， 7 （ 1 ）： 1339 .

王少明，郑荣寿，韩冰峰，等 . 2022年中国人群恶性肿瘤发病与死亡年龄特征分析 [J ] . 中国肿瘤， 2024 ， 33 （ 3 ）： 165 - 174 .

LI J K ， XU J Y ， YANG M Y ， et al . Therapeutic revolution for inoperable stage Ⅲ non-small cell lung cancer in the immune era [J ] . Cancer Biol Med ， 2022 ， 19 （ 5 ）： 569 - 572 .

QIN S K ， LI J ， ZHONG H J ， et al . Serplulimab，a novel anti-PD-1 antibody，in patients with microsatellite instability-high solid tumours：an open-label，single-arm，multicentre，phase Ⅱ trial [J ] . Br J Cancer ， 2022 ， 127 （ 12 ）： 2241 - 2248 .

CHENG Y ， HAN L ， WU L ， et al . Effect of first-line serplulimab vs. placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer：the ASTRUM-005 randomized clinical trial [J ] . JAMA ， 2022 ， 328 （ 12 ）： 1223 - 1232 .

刘梦娜，吴斌，艾丹丹，等 . 药物快速卫生技术评估方法学研究：以抗肿瘤用药为例 [J ] . 中国药房， 2022 ， 33 （ 11 ）： 1386 - 1391 .

李苗苗，吴雪，徐思敏，等 . 快速卫生技术评估的概况性综述 [J ] . 中国中药杂志， 2022 ， 47 （ 12 ）： 3125 - 3135 .

郭武栋，刘梦娜，潘伟，等 . 快速卫生技术评估国际经验介绍 [J ] . 中国医疗保险， 2022 （ 9 ）： 124 - 127 .

SHEA B J ， REEVES B C ， WELLS G ， et al . AMSTAR 2：a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions，or both [J ] . BMJ ， 2017 ， 358 ： j4008 .

HUSEREAU D ， DRUMMOND M ， AUGUSTOVSKI F ， et al . Consolidated health economic evaluation reporting standards 2022 （CHEERS 2022） statement：updated reporting guidance for health economic evaluations [J ] . Value Health ， 2022 ， 25 （ 1 ）： 3 - 9 .

CHEN C L ， TIAN P ， ZHONG J S ， et al . Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy in patients with extensive-stage small cell lung cancer：a systematic review and meta-analysis of randomized controlled trials [J ] . Front Oncol ， 2023 ， 13 ： 1151769 .

DU J C ， WANG X Y ， FAN L W ， et al . Effectiveness and safety of first-line immune checkpoint inhibitors for patients with extensive-stage small cell lung carcinoma：a systematic review and network meta-analysis [J ] . Heliyon ， 2023 ， 9 （ 4 ）： e14794 .

LI H J ， HAN H D ， LI C L ， et al . Efficacy and safety of first-line PD-1/PD-L1 inhibitor combinations for extensive-stage small-cell lung cancer：a Bayesian network meta-analysis [J ] . Ther Adv Med Oncol ， 2023 ， 15 ： 17588359231189430 .

LONGO V ， RIZZO A ， CATINO A ， et al . Safety evaluation of immune checkpoint inhibitors combined with chemotherapy for the treatment of small cell lung cancer：a meta-analysis of randomized controlled trials [J ] . Thorac Cancer ， 2023 ， 14 （ 11 ）： 1029 - 1035 .

SATHIYAPALAN A ， FEBBRARO M ， POND G R ， et al . Chemo-immunotherapy in first line extensive stage small cell lung cancer（ES-SCLC）：a systematic review and meta-analysis [J ] . Curr Oncol ， 2022 ， 29 （ 12 ）： 9046 - 9065 .

WANG S X ， LI Y S ， LIU Z Q ， et al . Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer：a network meta-analysis [J ] . Lung Cancer ， 2023 ， 178 ： 47 - 56 .

ZHANG T M ， LI W J ， DIWU D B ， et al . Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer：a Bayesian network meta-analysis [J ] . Front Immunol ， 2023 ， 14 ： 1197044 .

ZHAO W H ， WANG S F ， SU C Y ， et al . Efficacy of first-line immunotherapy combined with chemotherapy in extensive-stage small cell lung cancer patients with diffe- rent brain metastases status：a systematic review and meta-analysis [J ] . World J Oncol ， 2023 ， 14 （ 6 ）： 529 - 539 .

ZHU Y ， LIU K ， ZHU H ， et al . Comparative efficacy and safety of novel immuno-chemotherapy for extensive-stage small-cell lung cancer：a network meta-analysis of randomized controlled trial [J ] . Ther Adv Med Oncol ， 2023 ， 15 ： 17588359231206147 .

YANG C ， XUAN T T ， GONG Q ， et al . Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer：a network meta-analysis [J ] . Thorac Cancer ， 2024 ， 15 （ 15 ）： 1246 - 1262 .

GONG S Y ， LI Q ， YU X ， et al . Efficacy and safety of different immunotherapies combined with chemotherapy as first-line therapy in patients with small cell lung cancer：a network meta-analysis [J ] . Front Immunol ， 2024 ， 15 ： 1362537 .

KANG R T ， MA J L ， AI B ， et al . Efficacy and safety of immunotherapy combined with chemotherapy in patients with ES-SCLC：a systematic review and network meta-analysis of RCTs and RWSs [J ] . Thorac Cancer ， 2024 ， 15 （ 33 ）： 2375 - 2385 .

LIU Y ， ZHU J ， DU T Y ， et al . Navigating first-line therapies for extensive-stage small-cell lung cancer：a frequentist network meta-analysis and systematic review [J ] . Future Oncol ， 2024 ， 20 （ 28 ）： 2109 - 2122 .

齐冉，聂旭阳，刘旭婷，等 . 斯鲁利单抗联合化疗方案一线治疗广泛期小细胞肺癌的药物经济学评价 [J ] . 中国药房， 2023 ， 34 （ 11 ）： 1368 - 1373 .

KANG S ， LIU H L . Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China [J ] . Expert Rev Pharmacoecon Outcomes Res ， 2024 ， 24 （ 9 ）： 1081 - 1088 .

LIANG X Y ， CHEN X Y ， LI H J ， et al . Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer [J ] . Front Public Health ， 2023 ， 11 ： 1156427 .

LONG Y C ， XU Y ， LIAO L ， et al . Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China [J ] . BMJ Open ， 2023 ， 13 （ 8 ）： e072106 .

SHAO T H ， ZHAO M Y ， LIANG L Y ， et al . Serplulimab plus chemotherapy vs. chemotherapy for treatment of US and Chinese patients with extensive-stage small-cell lung cancer：a cost-effectiveness analysis to inform drug pricing [J ] . BioDrugs ， 2023 ， 37 （ 3 ）： 421 - 432 .

XIANG G Y ， JIANG T T ， GAN L L ， et al . Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China [J ] . Front Immunol ， 2023 ， 14 ： 1223020 .

ZHENG Z W ， CHEN H C ， CAI H F . Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer [J ] . Front Oncol ， 2024 ， 13 ： 1259574 .

ZHU Y W ， LIU K ， QIN Q ， et al . Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer：a cost-effectiveness analysis [J ] . Front Immunol ， 2023 ， 13 ： 1044678 .

YI L D ， ZHOU Z ， ZENG X H ， et al . First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy：a China-based cost-effectiveness analysis [J ] . Front Immunol ， 2024 ， 15 ： 1408928 .

Views

183

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Rapid health technology assessment of the efficacy， safety and cost-effectiveness of vericiguat in the treatment of heart failure

Semaglutide in the treatment of type 2 diabetes mellitus： rapid health technology assessment

Rapid health technology assessment of insulin icodec for the treatment of type 2 diabetes mellitus

Calcium channel modulators in the treatment of diabetic peripheral neuropathic pain： a rapid health technology assessment

Rapid health technology assessment of ulinastatin in the treatment of acute pancreatitis

Related Author

WANG Wei

HUANG Can

JIN Yong

KE Yijun

QI Lamei

WANG Sheng

WANG Yan

WANG Sihua

Related Institution

Dept. of Pharmaceutical Administration，Anqing Municipal Hospital

Dept. of Gastroenterology， Anqing Municipal Hospital

School Hospital of Anhui Medical University

Dept. of Pharmacy， Wannan Medical College

Dept. of Pharmacy， Yijishan Hospital of Wannan Medical College

⁰